新上市神经科药物的费用趋势:一项保险理赔数据库分析
本研究利用Merative MarketScan商业和Medicare补充数据库,分析2012至2021年9种神经科疾病中新上市药物(2014至2021年FDA批准)的年度和累计费用趋势。共纳入ALS、ATTR、DMD、HD、MG、偏头痛、OH、TD和SMA患者,偏头痛药物累计费用增幅最大(1993%),MG的eculizumab自付费用增幅达4099%。结论认为新上市神经科药物给患者和社会带来沉重且不断增加的经济负担。
要点
- 偏头痛药物的累计总费用增幅最大,达1993%。
- MG的eculizumab自付费用从413美元增至17359美元,增幅4099%。
- edaravone和deutetrabenazine的自付费用分别增加1775%和971%。
核心结论
- 新上市神经科药物给患者和社会带来沉重且不断增加的经济负担,而较老的仿制药未见此现象。
研究设计与样本
- 使用Merative MarketScan商业和Medicare补充数据库,观察2014至2021年FDA批准新药的9种神经科疾病患者,纳入2012至2021年至少有1次疾病相关处方配药者。
主要发现
- 共识别ALS 2687例、ATTR 38例、DMD 69例、HD 884例、MG 9984例、偏头痛441099例、OH 4723例、TD 1266例、SMA 17例。
- 偏头痛药物累计总费用增幅最大(1993%),平均自付费用增加234%(86美元至288美元)。
- MG的eculizumab自付费用增加4099%(413美元至17359美元),累计自付费用增加7005%(5375美元至381894美元)。
- edaravone自付费用从304美元增至5707美元(增幅1775%),deutetrabenazine从670美元增至7170美元(增幅971%)。
- DMD人群最年轻(平均25岁,SD=7),TD人群最年长(平均66岁,SD=14);DMD中99%为男性,偏头痛中84%为女性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Costs for neurologic medications have increased considerably in recent years. Since 2014, more than 30 neurologic medications have been approved by the US Food and Drug Administration (FDA) for neurologic conditions. This study aims to characterize recent trends in annual costs and aggregate spending from 2012 to 2021 for new-to-market (NTM) medications for 9 neurologic conditions. METHODS: We used the Merative MarketScan commercial and Medicare supplemental databases to observe patients seen by a neurologist with neurologic diseases with newly FDA-approved medications from 2014 to 2021: amyotrophic lateral sclerosis (ALS), transthyretin amyloidosis (ATTR), Duchenne muscular dystrophy (DMD), Huntington disease (HD), myasthenia gravis (MG), migraine, orthostatic hypotension (OH), tardive dyskinesia (TD), and spinal muscular atrophy (SMA). Patients were included if they had ≥1 disease-related prescription medication fill from 2012 to 2021. NTM (medications approved from 2014 to 2021) and older evidence-based guideline-supported medications were observed annually. Outcomes examined were annual and aggregate out-of-pocket (OOP) and total medication costs. RESULTS: We identified 2,687 unique individuals with ALS, 38 with ATTR, 69 with DMD, 884 with HD, 9,984 with MG, 441,099 with migraine, 4,723 with OH, 1,266 with TD, and 17 with SMA. The youngest population was DMD (mean = 25 years [SD = 7]), and the oldest was TD (mean = 66 years [SD = 14]). For DMD, the population was 99% male and for migraine, the population was 84% female, and the other conditions had more relatively even sex divides. Collectively, migraine medications had the largest increase in aggregate costs (1993%) and had a substantial increase in OOP costs on average by 234% ($86-$288). Eculizumab for MG was an extreme outlier, with OOP costs increasing by 4,099% ($413-$17,359) and aggregate OOP costs by 7,005% ($5,375-$381,894). OOP costs of edaravone ($304-$5,707) and deutetrabenazine ($670-$7,170) sharply increased by 1,775% and 971%, respectively. DISCUSSION: NTM medications for neurologic conditions have substantial and increasing individual and societal costs, which was not observed for older generic medications. These data suggest a need for policies to limit the financial burden of NTM medications on patients with neurologic conditions.
引用
- Gusovsky Chevalier AV, Lin CC, Kerber K, et al. Cost Trends of New-To-Market Neurologic Medications: An Insurance Claims Database Analysis. Neurology. 2025. PMID: 40014834. doi:10.1212/WNL.0000000000213428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。